Histological subtypes of lung adenocarcinoma have differential 18F-fluorodeoxyglucose uptakes on the positron emission tomography/computed tomography scan

Journal of Thoracic Oncology

Volumn 6, Issue 10, 2011, Pages 1697-1703

  Chiu, Chao Hua ^a,b,c   Yeh, Yi Chen ^a,c   Lin, Ko Han ^c   Wu, Yu Chun ^c   Lee, Yu Chin ^b,c   Chou, Teh Ying ^a,c   Tsai, Chun Ming ^b,c  

^a Institute of Clinical Medicine   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Glucose transporter type 1; Histological subtyping; Lung adenocarcinoma; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1;

ACINAR CELL CARCINOMA; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER SIZE; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG RESECTION; MALE; PAPILLOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; WEDGE RESECTION;

EID: 80053047223     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318226b677     Document Type: Article

References (31)

1. Deberardinis RJ, Sayed N, Ditsworth D, et al. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008;18:54-61. (Pubitemid 351694453)
2. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008;134:703-707.
3. Warburg O. On the origin of cancer cells. Science 1956;123:309-314.
4. Pauwels EK, Sturm EJ, Bombardieri E, et al. Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol 2000;126:549-559.
5. Aquino SL, Halpern EF, Kuester LB, et al. FDG-PET and CT features of non-small cell lung cancer based on tumor type. Int J Mol Med 2007;19:495-499.
6. de Geus-Oei LF, van Krieken JH, Aliredjo RP, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 2007;55:79-87. (Pubitemid 46038871)
7. Suzawa N, Ito M, Qiao S, et al. Assessment of factors influencing FDG uptake in non-small cell lung cancer on PET/CT by investigating histological differences in expression of glucose transporters 1 and 3 and tumour size. Lung Cancer 2011;72:191-198.
8. Travis WD, Brambilla E, Muller-Hermelink HK, et al. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004.
9. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
10. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008;32:810-827.
11. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 2010;34:1155-1162.
12. Bryant CM, Albertus DL, Kim S, et al. Clinically relevant characteriza tion of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. PLoS One 2010;5:e11712.
13. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 2002;26:767-773. (Pubitemid 34546942)
14. Yatabe Y, Kosaka T, Takahashi T, et al. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 2005; 29:633-639. (Pubitemid 40577873)
15. Yatabe Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev 2010;29:23-36.
16. Goldstraw P. IASLC Staging Manual in Thoracic Oncology. Orange Park, FL: International Association for the Study of Lung Cancer; Editorial Rx Press; 2009.
17. Wu YC, Su LJ, Wang HW, et al. Co-overexpression of cyclooxygenase- 2 and microsomal prostaglandin E synthase-1 adversely affects the postoperative survival in non-small cell lung cancer. J Thorac Oncol 2010;5:1167-1174.
18. Kerr KM. Pulmonary adenocarcinomas: classification and reporting. Histopathology 2009;54:12-27.
19. Riquet M, Foucault C, Berna P, et al. Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping. Ann Thorac Surg 2006;81:1988-1995. (Pubitemid 43775587)
20. Sakurai H, Dobashi Y, Mizutani E, et al. Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter: a prognostic assessment. Ann Thorac Surg 2004;78:1728-1733. (Pubitemid 39423543)
21. Nguyen XC, Lee WW, Chung JH, et al. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Eur J Radiol 2007;62:214-219. (Pubitemid 46560344)
22. van Baardwijk A, Dooms C, van Suylen RJ, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 2007;43:1392-1398. (Pubitemid 46874072)
23. Kim BT, Kim Y, Lee KS, et al. Localized form of bronchioloalveolar carcinoma: FDG PET findings. AJR Am J Roentgenol 1998;170:935-939. (Pubitemid 28172876)
24. Heyneman LE, Patz EF. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer 2002;38:261-266. (Pubitemid 35341800)
25. Sun JS, Park KJ, Sheen SS, et al. Clinical usefulness of the fluorodeoxyglucose (FDG)-PET maximal standardized uptake value (SUV) in combination with CT features for the differentiation of adenocarcinoma with a bronchioloalveolar carcinoma from other subtypes of non-small cell lung cancers. Lung Cancer 2009;66:205-210.
26. Na II, Byun BH, Kim KM, et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung Cancer 2010;67:76-80.
27. Mak RH, Digumarthy SR, Muzikansky A, et al. Role of 18F- fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncologist 2011;16:319-326.
28. Huang CT, Yen RF, Cheng MF, et al. Correlation of F-18 fluorodeoxyglucose- positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med Oncol 2010;27:9-15.
29. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in nonsmall- cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005; 23:857-865. (Pubitemid 46224186)
30. Hsieh RK, Lim KH, Kuo HT, et al. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest 2005;128:317-321.
31. Haneda H, Sasaki H, Lindeman N, et al. A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. Jpn J Clin Oncol 2006;36:69-75.